Phaseline

Targets › GLS

GLS (Glutaminase kidney isoform, mitochondrial): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 5 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Nov 2026.

Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. (UniProt, O94925)

Open in Phaseline: the race on GLS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Telaglenastat
Glutaminase kidney isoform, mitochondrial inhibitor
GLSPhase 2Advanced Malignant Solid Neoplasm; Leptomeningeal Neoplasm; Advanced Lung Non-Small Cell Carcinoma; Recurrent Multiple Myeloma …Nov 2026
Douglas Postels, MD, MS6-diazo-5-oxo-L-norleucine (DON)
Glutaminase inhibitor; inhibits de novo nucleotide synthesis via glutamine antagonism
GLSPhase 1Malaria, CerebralNov 2028

Conditions

Advanced Malignant Solid Neoplasm (1) Leptomeningeal Neoplasm (1) Advanced Lung Non-Small Cell Carcinoma (1) Recurrent Multiple Myeloma (1) Astrocytoma, IDH-Mutant, Grade 2 (1) Malaria, Cerebral (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

National Cancer Institute (NCI) (1) Douglas Postels, MD, MS (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.